Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Director | March 19, 2026 | March 23, 2026 |
| Calithera Biosciences, Inc.CALA · Entity 113073 | See Remarks | January 23, 2023 | January 25, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2031-04-29 | Direct | 24,999 |
Reported balance
After 2026-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 24,999 · Balance 24,999 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2031-04-29 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Disposition to issuer · Disposed 24,999 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-05-11 | Direct | 10,362 |
Reported balance
After 2026-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-19 · Grant · Acquired 10,362 · Balance 10,362 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.28 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-19 · Disposition to issuer · Disposed 10,362 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2033-06-06 | Direct | 23,742 |
Reported balance
After 2026-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-19 · Grant · Acquired 23,742 · Balance 23,742 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.91 · Expires 2033-06-06 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-19 · Disposition to issuer · Disposed 23,742 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
F2: The option is fully vested.
F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
Calithera Biosciences, Inc.
Report date January 23, 2023 · Filed January 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,287 |
Reported balance
After 2023-01-23 transaction · row 1
1 source rowRow 1 · 2023-01-23 · Tax withholding · Disposed 317 · Balance 6,287 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 360 |
Reported balance
Holding disclosure · report date 2023-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 360 F3: Shares were held by the Wong Family Trust, of which the reporting person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
F3: Shares were held by the Wong Family Trust, of which the reporting person is a trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 23:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $5.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120216 · ownership.xml · derivative · entry 6 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120216 · ownership.xml · derivative · entry 5 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 10,362 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120216 · ownership.xml · derivative · entry 4 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 10,362 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120216 · ownership.xml · derivative · entry 3 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 24,999 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001193125-26-120216 · ownership.xml · derivative · entry 2 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,999 shares Expires 2031-04-29 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 24,999 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120216 · ownership.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,999 Underlying: Common Stock · 24,999 shares Expires 2031-04-29 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:28 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064089 · ownership.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-02-19 F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:56 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 19,111 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-25-077053 · ownership.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 Underlying: Common Stock · 19,111 shares Expires 2035-05-21 F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:50 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 64,503 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076361 · ownership.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,503 Underlying: Common Stock · 64,503 shares Expires 2034-06-18 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 00:49 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0000899243-23-015317 · doc4.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 16:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Tax withholdingCommon Stock | 317 | $0.45 | $141.41 |
DisclosureSEC source: 0000899243-23-002609 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,287 F1 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 10,362 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018289 · doc4.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:17 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000899243-22-003440 · doc4.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 25, 2022; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Tax withholdingCommon Stock | 5,586 | $0.49 | $2,745.52 |
DisclosureSEC source: 0000899243-22-003138 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,085 F1 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Tax withholdingCommon Stock | 18,077 | $0.66 | $11,938.05 |
DisclosureSEC source: 0000899243-22-001298 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,671 F1 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 4, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 19:34 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Tax withholdingCommon Stock | 15,566 | $0.87 | $13,542.42 |
DisclosureSEC source: 0000899243-21-043687 · doc4.xml · nonDerivative · entry 2 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,748 F2 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 8, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 19:34 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043687 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,314 F1 · shares: The shares of Common Stock were acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 18:50 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Tax withholdingCommon Stock | 45,965 | $1.89 | $86,873.85 |
DisclosureSEC source: 0000899243-21-042068 · doc4.xml · nonDerivative · entry 2 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,314 F2 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on October 28, 2021 and October 29, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 18:50 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042068 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,279 F1 · shares: The shares of Common Stock were acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:13 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0000899243-21-003037 · doc4.xml · derivative · entry 3 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-20 F4 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 20, 2021; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:13 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003037 · doc4.xml · nonDerivative · entry 2 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,156 F3 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on January 3, 2022. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:13 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003037 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,156 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest as follows: one-fourth (1/4th) of the shares subject to the Restricted Stock Unit will vest each year after January 20, 2021 until the Restricted Stock Units are fully vested. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. F2 · balance_after: Includes 855 shares acquired June 10, 2020, and 1,342 shares acquired December 10, 2020 under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | SaleCommon Stock | 5,000 | $8.00 | $40,000.00 |
DisclosureSEC source: 0000899243-20-010902 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · SR. VP, FINANCE & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,082 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Trading Plan. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 18:12 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0000899243-20-001694 · doc4.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · SR. VP, FINANCE & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-01-17 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 17, 2020; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-19-017790 · doc4.xml · derivative · entry 3 Wong Stephanie · CIK 0001555744 · SR. VP, FINANCE & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,284 Underlying: Common Stock · 10,000 shares Expires 2024-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-forty-eighth (1/48th) of the Option vests in equal monthly installments one month after April 1, 2014. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 10,000 | $2.64 | $26,400.00 |
DisclosureSEC source: 0000899243-19-017790 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · SR. VP, FINANCE & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500, 2,500 and 1,751 shares acquired under the Company's 2014 Employee Stock Purchase Plan on June 8, 2018, December 10, 2018 and June 10, 2019, respectively. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:30 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000899243-19-001126 · doc4.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · SR. VP, FINANCE & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-01-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 10, 2019; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 19:26 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-18-005710 · doc4.xml · derivative · entry 3 Wong Stephanie · CIK 0001555744 · SR VP, FINANCE AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,596 Underlying: Common Stock · 10,000 shares Expires 2024-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-forty-eighth (1/48th) of the Option vests in equal monthly installments one month after April 1, 2014. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 19:26 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 10,000 | $2.64 | $26,400.00 |
DisclosureSEC source: 0000899243-18-005710 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · SR VP, FINANCE AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on December 8, 2017. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 16:07 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0000899243-18-001075 · doc4.xml · derivative · entry 1 Wong Stephanie · CIK 0001555744 · SR. VP, FINANCE & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-10 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 11, 2018; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 16:06 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | SaleCommon Stock | 3,552 | $18.41 | $65,384.51 |
DisclosureSEC source: 0000899243-17-018552 · doc4.xml · nonDerivative · entry 1 Wong Stephanie · CIK 0001555744 · VP, FINANCE AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,550 F1 · kind: Reported transaction occurred pursuant to a Rule10b5-1 Trading Plan adopted on June 16, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.90 to $18.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · ownership.nature: Shares were held by the Wong Family Trust, of which the reporting person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.